Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 70518-1897

7 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-1897). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Divalproex Sodium 500mg 70518 1897 01

Divalproex Sodium 500mg 70518 1897 01
Label for Divalproex Sodium extended-release 500 mg film-coated tablets, quantity of 100. The label indicates oral dosage form and mentions repackaging by RemedyRepack Inc. It includes manufacturer information for Aurobindo Pharma, Dayton, NJ, and storage instructions.*
FDA Label Image

Divalproex Sodium 500mg 70518 1897 02

Divalproex Sodium 500mg 70518 1897 02
Label for Divalproex Sodium extended-release 500 mg tablet, quantity 1. The label includes NDC 70518-1897-02, manufacturer Aurobindo Pharma, and repackager RemedyRepack Inc. Directions advise storage at 20-25°C with excursions permitted to 15-30°C and reference the package insert for use instructions.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Label for Divalproex Sodium 500 mg extended-release film-coated tablets. The package contains 30 tablets. The label includes the NDC number, manufacturer Aurobindo Pharma in Dayton, NJ, and indicates repackaging by RemedyRepack Inc. Directions advise storage at 20-25°C with permitted excursions and to see the package insert for use. The label has a purple highlight behind the strength and the RemedyRepack logo.*
FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
A line graph comparing the percentage reduction in CPS rate between Divalproex Sodium Delayed-Release Tablets and Placebo. The x-axis shows the percentage of patients, and the y-axis indicates improvement or worsening based on percentage reduction in CPS rate, with two curves representing the effects of the drug and placebo respectively.*
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
This figure is a cumulative percentage plot showing % Reduction in CPS Rate on the vertical axis versus % of Patients on the horizontal axis for Divalproex Sodium delayed-release tablets. It compares high dose and low dose tablets, plotting patient response from worsening to improvement.*
FDA Label Image

Figure-3 (Divalproex Fig3)

Figure-3 (Divalproex Fig3)
A bar chart comparing two groups: placebo and Divalproex sodium extended-release tablets. The y-axis ranges from 0 to 1.2, showing values 0.6 for placebo and 1.2 for Divalproex sodium extended-release tablets. An asterisk notes statistical significance with p=0.006.*
FDA Label Image

Structure (Divalproex Str)

Structure (Divalproex Str)
Chemical structure of divalproex sodium, showing its molecular composition with sodium ions and associated hydrocarbon chains arranged in a polymeric form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.